MARCELO BELLESSO
Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Less Intensive Regimens May Still Be Suitable for the Initial Treatment of Primary Mediastinal B-Cell Lymphoma in Resource-Limited Settings(2022) VELASQUES, Rodrigo Dolphini; SILVA, Wellington F. da; BELLESSO, Marcelo; ROCHA, Vanderson; PEREIRA, JulianaPrimary mediastinal B-cell lymphoma (PMBCL) is an uncommon disease, consisting of 2-4% of non-Hodgkin lymphomas. Radiotherapy-free DA-EPOCH-R and R-CHOP plus radiotherapy (RT) have been the upfront standard regimens worldwide. However, performing DA-EPOCH-R in resource-constrained settings can be burdensome, especially in low/middle-income countries, where data on PMBCL are still largely unknown. We retrospectively analyzed 93 patients with PMBCL diagnosed between 2008 and 2018 with the intention of comparing the characteristics of the patients and the results obtained with each protocol and to verify if the use of less intensive chemotherapy is still possible to be used. The median age was 28 years, 59.1% were female, 42.3% were in advanced stages, and 92.1% were with bulky disease. DA-EPOCH-R (41.9%), R-CHOP (35.5%), and R-CHOEP (22.6%) were the regimens used, and no difference was observed in the characteristics of the patients. After four cycles of chemotherapy, complete response (CR), partial response (PR), and progressive disease (PD) rates were 40%, 55.7%, and 4.5%, respectively. At the end of treatment, metabolic CR and PD rates were 56.8% and 11.1%. RT was performed in 42.1% of DA-EPOCH-R, 75% of R-CHOP, and 83% of R-CHOEP, and switched PR to CR in 73.7%. Estimated 5-year PFS and OS were 77.2% and 77.4%, respectively. Only LDH levels remained independently associated with PFS, and type of treatment was not associated with OS, PFS, or relapse rate. Therefore, we conclude that in a resource-constrained setting, R-CHOP or R-CHOEP could be still safely adopted in upfront treatment for PMBCL.
- How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation(2020) PERINI, Guilherme Fleury; FISCHER, Thais; GAIOLLA, Rafael Dezen; ROCHA, Talita Bueno; BELLESSO, Marcelo; TEIXEIRA, Larissa Lane Cardoso; DELAMAIN, Marcia Torresan; SCHELIGA, Adriana Alves de Souza; RIBEIRO, Glaciano Nogueira; NETO, Jorge Vaz; BAIOCCHI, Otavio Cesar Carvalho Guimaraes; ABDO, Andre Neder Ramires; ARRAIS-RODRIGUES, Celso; FOGLIATTO, Laura M.; BIGNI, Ricardo de Sa; SCHAFFEL, Rony; BIASOLI, Irene; PEREIRA, Juliana; NABHAN, Samir Kanaan; SOUZA, Carmino Antonio de; CHIATTONE, Carlos SergioThe novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients. (C) 2020 Published by Elsevier Editora Ltda. on behalf of Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular.
- Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study(2020) SILVA, Wellington F. da; GARIBALDI, Pedro Manoel Marques; ROSA, Lidiane Ines da; BELLESSO, Marcelo; CLE, Diego Villa; DELAMAIN, Marcia Torresan; REGO, Eduardo Magalhaes; PEREIRA, Juliana; ROCHA, VandersonBackground: Although the increased use of combined antiretroviral therapy (cART) has decreased the incidence of lymphomas HIV-associated, Burkitt lymphoma (BL) incidence remains stable. Reported outcomes on HIV-associated BL from developed countries seem to corroborate that the regimens do not need to be tailored to the HIV-positive population. Materials and methods: This is a retrospective multicenter cohort study from Brazil, including HIV-positive patients aged 15 years and above diagnosed with BL. Results: A total of 54 patients were included. Median age was 39 years (range, 15-64). At diagnosis, advanced disease was found in 86% and 52% had a CD4+ count lower than 200 cells/mm(3). Five patients died before starting any regimen. Among the remaining 49 patients, most were treated with Hyper-CVAD (53%) and CODOX-M IVAC (18%). Rituximab was used in frontline in only 16% of the patients. Primary refractory disease was found in 14%. A treatment-related mortality of 38.7% and a complete response rate of 44.9% were found. At 4 years, estimated overall survival (OS) was 39.8%. All relapsed and primary refractory patients eventually died. Remaining patients died from infections (24/34), despite antimicrobial prophylaxis and associated cART. Conclusion: Early mortality and toxicity were higher in our cohort than in developed countries. A faster diagnosis, better understanding of the biology of the disease, establishment of low toxicity regimens, inclusion of rituximab and improvement of supportive care may decrease the mortality of HIV-associated BL in developing countries.
- Rescue of chemorefractory classical Hodgkin lymphoma with nivolumab and autologous stem-cell transplantation: Real-life experience(2021) BUCCHERI, Valeria; FATOBENE, Giancarlo; SANTOS, Fernanda M.; VELASQUES, Rodrigo D.; BELLESSO, Marcelo; ATANAZIO, Marcelo J.; ROCHA, Vanderson